Chemistry: analytical and immunological testing – Optical result
Reexamination Certificate
2000-11-07
2003-05-06
Ludlow, Jan (Department: 1743)
Chemistry: analytical and immunological testing
Optical result
C073S866000, C073S866500, C422S082010, C422S082050, C422S082090, C422S082110, C436S151000, C436S173000, C436S181000
Reexamination Certificate
active
06558957
ABSTRACT:
BACKGROUND OF THE INVENTION
Dissolution testing is required for all solid oral pharmaceutical solid dosage form forms in which absorption of the drug is necessary for the product to exert the desired therapeutic effect. The U.S. Pharmacopeia (USP) is one well-known standard source of information which provides for dissolution and drug release testing in the majority of monographs for such dosage forms. Exceptions are for tablets meeting a requirement for completeness of solution or for rapid (10 to 15 minutes) disintegration for soluble or radiolabled drugs. The apparatus and procedure conform to the requirements and specifications given, e.g., USP 23rd edition Chapter 711 (Dissolution) pages 1791-1793. Dissolution testing serves as a measure of quality control, stability and uniformity as well as a means by which to correlate in-vitro with in-vivo drug release characteristics.
Current USP dissolution methods most commonly employ a temperature programmable water bath, maintained at about 37° C., in which sample vessels are submerged. These vessels contain a predetermined volume of a dissolution media and a means to agitate the contents of the vessel. This may be accomplished by means of a rotating basket attached to a shaft or with a paddle which is also attached to a shaft, both means generally described in USP 23rd edition Chapter 711 (Dissolution) pages 1791-1793. The solid dosage form is placed into the media filled vessel at time zero and specific vessel temperature and mixing speeds are maintained. At fixed time intervals (e.g. 2, 4, 8 hours, etc.) a small aliquot of sample is taken from each vessel, usually by a multi channeled pumping system, and transported to either a cuvette or a sample vial for subsequent spectrophotometric or high pressure liquid chromatography (HPLC) analysis, respectively. Plotting percentage dissolution of a solid dosage form through time results in a dissolution profile.
Of the two methods discussed above, the HPLC method is usually favored over the spectrophotometric method. While HPLC dissolution offers the advantage of specificity, acceptable accuracy, precision and sensitivity, the disadvantage of the status quo rather lies with the inherent burden of creating, manipulating, and storing voluminous numbers of sequence and data files. The cost of HPLC, columns, mobile phases, and the waste solvent disposal, etc., is substantial and the limited number of data points that can be determined may result in a less than ideal representation of the release profile of a solid dosage form over time. Furthermore, HPLC analysis is a sequential time consuming process. In general, a typical 24 hour dissolution requires up to 60 hours to generate a dissolution profile.
Because of the aforementioned disadvantages of currently available systems, an in-situ dissolution method is desirable.
SUMMARY OF THE INVENTION
The present invention relates to an improvement in a detection system used for continuously measuring the release of a drug from a pharmaceutical dosage form comprising a singular dissolution vessel or multiple dissolution vessels containing a dissolution medium and a measuring device for detecting the amount of drug released at a given time, the improvement comprising a mixing shaft and a probe placed within the mixing shaft or outside the individual dissolution vessels, the probe capable of measuring the dissolution characteristics using UV, IR, near-IR, fluorescence, electrochemical, nuclear magnetic resonance (NMR), and Raman spectroscopy techniques.
The present invention also relates to a method for predicting the dissolution curve provided by a controlled release pharmaceutical dosage form comprising taking continuous measurements of the amount of drug released from a dosage form for a portion of the time over which the drug is expected to be released and predicting the remainder of the dissolution curve based on the values obtained.
The present invention relates to a in-situ dissolution methods to evaluate and study the dissolution characteristics of drug formulations. Such methods utilize systems that include fiber optics, ultraviolet spectroscopy, fluorescence spectroscopy, NMR and the like.
The present invention specifically relates to detection systems for measuring dissolution characteristics of pharmaceutical dosage forms using ultraviolet, IR, near-IR, and Raman spectroscopy techniques as well as electrochemical techniques such as polarography, and NMR.
These and other aspects of the present invention can be followed by one skilled in the art by reading the detailed description and the methods provided by the instant invention.
REFERENCES:
patent: 4335438 (1982-06-01), Smolen
patent: 5098659 (1992-03-01), Yim et al.
patent: 5133892 (1992-07-01), Chun et al.
patent: 5142920 (1992-09-01), Bart et al.
patent: 5589649 (1996-12-01), Brinker et al.
patent: 5638174 (1997-06-01), Henderson
patent: WO9523329 (1995-08-01), None
Optical Fiber Spectrometry in Turbid Solutions by Multivariate Calibration Applied to Tablet Dissolution Testing, Analytical Chemistry, Dec. 1988, pp. 2666-2671.
Biosensors, Journal of Chromatography, Christopher R. Lowe, et al., 1990, pp. 347-354.
Optically-based chemical and biochemcial sensors for the detectioin of some drugs and biological compounds, P.R. Coulet, L.J. Blum; and S. M. Gautier, Journal of Pharmaceutical & Biomedical Analysis, 1989, vol. 7, No. 12, pp. 1361-1376.
The Nature of biosensor technology, J. C. Cooper and E. A. H. Hall, J. Biomed. Eng., May, 1988, pp. 210-219.
Biosensors Theory and Applications, Donald G. Buerk, Ph.D., Technomic Publishing Co., 1993, pp. 125-149.
Analytical Applications of Optical Imaging Fibers, Paul Pantano and David R. Walt, American Chemistry Society, 1995, pp. 481-487.
Transducer mechanisms for optical biosensors. Part 2: Transducer design, D.C. Ashworth and R. Narayanaswamy, Computer Methods and Programs in Biomedicine, 30, 1989, pp. 21-31.
Process Analytical Chemistry, Wayne W. Blaser, et. al., American Chemical Society, 1995, pp. 47R-70R.
Second-Order Fiber Optical Heavy Metal Sensor Employing Second-Order Tensorial Calibration, Zhihao Lin, et al. Anallytical Chemistry, Aug. 1, 1994, pp. 2552-2560.
FIP Guidelines for Dissolution Testing of Solid Oral Products, Joint Report of the Section for Official Laboratories and Medicines Control Services and the Secion of Industrial Pharmacists of the F.I.P., Pharmacopetai Forum, vol. 21, No. 5, Sep.-Oct., 1995.
Chemical Abstract No. 124:15590CA,Feasibility of fluorescence detection of tetracycline in media mixturesemploying a ***fiber*** ***optic*** ***probe***, (1995), pp. 1-2.
Cho et al., Anal. Chem. vol. 67, pp. 2858-2863 (1995).*
Aldridge et al., J. Pharma. Sci., vol. 84, No. 8, pp. 909-914 (1995).
Bynum Kevin
Cheng Frank S.
Palermo Philip J.
Roinestad Kurt
Delphian Technology, Inc.
Ludlow Jan
Weingarten Schurgin, Gagnebin & Lebovici LLP
LandOfFree
Detection systems and methods for predicting the dissolution... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Detection systems and methods for predicting the dissolution..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Detection systems and methods for predicting the dissolution... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3014863